Company intelligence / Profile preview

Novassay

Epalinges / Lausanne region / Yverdon-les-Bains*, Switzerlandnovassay.com ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Novassay is developing a pipeline of ion channel-targeting therapeutics for neuropathic pain and oncology. Its lead small molecule candidate NVA1309 is at the GLP/toxicology stage with unique properties such as non-brain penetration and high potency over pregabalin. The company also has monoclonal antibody programs targeting α2δ subunits for both neurological diseases and cancer. No clinical results have been reported yet[3][7].

Therapeutic areas: OncologyNeurology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Drug pipeline

3 assets

NVA1501-16

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships publicly disclosed as of June 2025. The company expresses interest in R&D collaborations[1].

Beyond the preview

Go deeper on Novassay.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novassay.

Explore the full profile